Finance

Lists
RVMD:NASDAQ
Revolution Medicines Inc
204,48 USD
+1,36%
(+2,74) 1D
204,48 USD
0,00% (0,00)
After hours
Closed: 29-сен., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RVMD...
Open
201,41 USD
High
204,96 USD
Low
200,00 USD
Mkt. cap
43,83 млд
Avg. vol.
2,06 млн
Volume
1,72 млн
52-wk high
224,31 USD
52-wk low
45,49 USD
EPS
-8,83 USD
Beta
1,40
Shares outstanding
214,34 млн
No. of employees
883
Open
201,41 USD
High
204,96 USD
Low
200,00 USD
Mkt. cap
43,83 млд
Avg. vol.
2,06 млн
Volume
1,72 млн
52-wk high
224,31 USD
52-wk low
45,49 USD
EPS
-8,83 USD
Beta
1,40
Shares outstanding
214,34 млн
No. of employees
883
News stories
From web sources and news partners
About Revolution Medicines Inc
CEO-
Employees883
Founded2014
HeadquartersРедвуд Сити, Калифорния, Америка Кошмо Штаттары
Sector-
Websiterevmed.com
Analyst ratings
Based on 23 analysts giving stock ratings to RVMD in the past 3 months
Strong buy
Buy
22
Hold
1
Sell
0
12-month forecast
Based on 23 Wall Street analysts offering 12 month price targets for RVMD in the last 3 months.
Highest
Current 204,48 USD
320,00 USD (+56,49%)
Average
257,81 USD (+26,08%)
Lowest
179,00 USD (-12,46%)
Analyst
Recommendation
Action
Price target
Projected
Date
Charles Zhu
LifeSci Capital
Buy
Maintained
315,00 USD
+54%
09/28/2026
Leah R. Cann
Brookline Capital Markets
Buy
Initiated
318,00 USD
+55,5%
09/28/2026
Jeffrey Walch
Bernstein
Hold
Maintained
179,00 USD
-12,5%
09/25/2026
Andrea Newkirk
Goldman Sachs
Buy
Initiated
267,00 USD
+30,6%
09/24/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
265,00 USD
+29,6%
09/21/2026
Leonid Timashev
RBC Capital
Buy
Maintained
251,00 USD
+22,8%
09/16/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
230,00 USD
+12,5%
09/13/2026
Sean Laaman
Morgan Stanley
Buy
Initiated
255,00 USD
+24,7%
09/10/2026
Faisal Khurshid
Jefferies
Buy
Maintained
270,00 USD
+32%
09/03/2026
Gregory Renza
Truist Financial
Buy
Maintained
-
-
09/03/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
246,00 USD
+20,3%
09/01/2026
Ami Fadia
Needham
Buy
Reiterated
275,00 USD
+34,5%
08/31/2026
Michael Yee
UBS
Buy
Maintained
265,00 USD
+29,6%
08/28/2026
Sean McCutcheon
Raymond James
Buy
Maintained
248,00 USD
+21,3%
08/27/2026
Jay Olson
Oppenheimer
Buy
Maintained
260,00 USD
+27,2%
08/27/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
320,00 USD
+56,5%
08/27/2026
Michael Schmidt
Guggenheim
Buy
Maintained
275,00 USD
+34,5%
08/27/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Reiterated
240,00 USD
+17,4%
08/27/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
280,00 USD
+36,9%
08/27/2026
Robert Driscoll
Wedbush
Buy
Maintained
225,00 USD
+10%
08/27/2026
Kalpit Patel
Wolfe Research
Buy
Maintained
220,00 USD
+7,6%
08/10/2026
Marc Frahm
TD Cowen
Buy
Reiterated
-
-
08/10/2026
Joseph Catanzaro
Mizuho Securities
Buy
Reiterated
215,00 USD
+5,1%
08/05/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
210,00 USD
+2,7%
08/06/2026
Unknown Analyst
Bernstein
Hold
Maintained
151,00 USD
-26,2%
06/07/2026
Michael Morris
Guggenheim
Buy
Maintained
175,00 USD
-14,4%
04/22/2026
Jonathan Chang
Leerink Partners
Buy
Reiterated
147,00 USD
-28,1%
04/13/2026
Asthika Goonewardene
Truist Financial
Buy
Maintained
-
-
03/09/2026
Last report
2026-ж., 5-авг.
Fiscal period
Q2 2026
EPS / Est. (USD)
-3,06 USD / -2,07 USD
-48,03%miss
Revenue / Est. (USD)
- / 16,37 млн
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
262,51 млн
294,94 млн
343,97 млн
394,92 млн
Cost of revenue
262,51 млн
294,94 млн
343,97 млн
394,92 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
52,76 млн
66,68 млн
101,25 млн
110,21 млн
Operating expense
52,76 млн
66,68 млн
101,25 млн
110,21 млн
Total operating expenses
315,27 млн
361,63 млн
445,22 млн
505,13 млн
Operating income
-315,27 млн
-361,63 млн
-445,22 млн
-505,13 млн
Other non operating income
-592,00 миң
-12,62 млн
-15,90 млн
-151,04 млн
EBT including unusual items
-305,21 млн
-364,89 млн
-453,82 млн
-644,37 млн
EBT excluding unusual items
-305,21 млн
-364,89 млн
-453,82 млн
-644,37 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-305,21 млн
-364,89 млн
-453,82 млн
-644,37 млн
Net profit margin
-
-
-
-
Earnings per share
-1,61
-1,86
-2,29
-3,06
Interest and investment income
22,08 млн
21,29 млн
19,51 млн
35,58 млн
Interest expense
-11,43 млн
-11,94 млн
-12,20 млн
-23,78 млн
Net interest expenses
10,66 млн
9,36 млн
7,31 млн
11,80 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-313,24 млн
-359,39 млн
-442,88 млн
-502,68 млн
Gain or loss from assets sale
32,00 миң
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору